Patient outcomes and clinician perspectives following one year of <i>ad hoc</i> implementation of neoadjuvant endocrine therapy in early breast cancer.

ABSTRACT:

Background

Neoadjuvant endocrine therapy (NAET) can induce a reduction of Ki-67 in hormone receptor-positive breast cancer, predicting response to adjuvant endocrine therapy and potentially allowing patients to forego chemotherapy without increasing recurrence risk. However, Ki-67 interpretation is highly variable. Implementation requires careful multidisciplinary planning to mitigate the effects of Ki-67 variability on treatment eligibility. Feasibility and short-term oncological outcomes of implementation of short-course NAET were studied during a "window of opportunity" where it was adopted by several unit surgeons without formal pathway development. A concurrent qualitative study identified barriers to NAET from surgeons' perspectives and gained insight from pathologists about

SUBMITTER: Fennelly S 

PROVIDER: S-EPMC12593990 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature